2seventy bio, Inc.
TSVT
$12.15
$0.070.58%
Weiss Ratings | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -- | |||
Price History | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 1.67% | |||
30-Day Total Return | 41.94% | |||
60-Day Total Return | 13.45% | |||
90-Day Total Return | -4.63% | |||
Year to Date Total Return | 30.79% | |||
1-Year Total Return | 4.11% | |||
2-Year Total Return | -- | |||
3-Year Total Return | -- | |||
5-Year Total Return | -- | |||
52-Week High % Change | -35.65% | |||
52-Week Low % Change | 47.27% | |||
Price | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $18.88 | |||
52-Week Low Price | $8.25 | |||
52-Week Low Price (Date) | Apr 24, 2023 | |||
52-Week High Price (Date) | Aug 10, 2022 | |||
Valuation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | $609.92M | |||
Enterprise Value | 535.51M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -5.46 | |||
Earnings Per Share Growth | -54.22% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 4.24 | |||
Price/Book (Q) | 1.52 | |||
Enterprise Value/Revenue (TTM) | 4.29 | |||
Price | $12.15 | |||
Enterprise Value/EBITDA (TTM) | -2.51 | |||
Enterprise Value/EBIT | -2.39 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 43.468M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 339 499 9300 | |||
Address | 60 Binney Street Cambridge, MA 02142 | |||
Website | www.2seventybio.com | |||
Country | United States | |||
Year Founded | 2021 | |||
Profitability | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -179.65% | |||
Profit Margin | -172.80% | |||
Management Effectiveness | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -17.56% | |||
Return on Equity | -- | |||
Income Statement | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | $124.69M | |||
Total Revenue (TTM) | $124.69M | |||
Revenue Per Share | $2.87 | |||
Gross Profit (TTM) | -$153.03M | |||
EBITDA (TTM) | -$213.75M | |||
EBIT (TTM) | -$224.01M | |||
Net Income (TTM) | -$215.46M | |||
Net Income Avl. to Common (TTM) | -$215.46M | |||
Total Revenue Growth (Q YOY) | 393.78% | |||
Earnings Growth (Q YOY) | 45.14% | |||
EPS Diluted (TTM) | -$5.46 | |||
EPS Diluted Growth (Q YOY) | 66.24% | |||
Balance Sheet | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | $339.93M | |||
Cash Per Share (Q) | $7.82 | |||
Total Current Assets (Q) | $389.82M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | $401.32M | |||
Current Ratio (Q) | 5.067 | |||
Book Value Per Share (Q) | $8.00 | |||
Total Assets (Q) | $742.44M | |||
Total Current Liabilities (Q) | $76.93M | |||
Total Debt (Q) | $266.95M | |||
Total Liabilities (Q) | $341.11M | |||
Total Common Equity (Q) | $401.32M | |||
Cash Flow | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | $11.75M | |||
Cash from Financing (TTM) | $123.21M | |||
Net Change in Cash (TTM) | -$77.20M | |||
Levered Free Cash Flow (TTM) | -$159.87M | |||
Cash from Operations (TTM) | -$212.16M | |||